Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Ophthalmology and OptometryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence of hyperthyroidism in Sweden.Eur J Endocrinol. 2011; 165: 899-905
- The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.Trans Am Ophthalmol Soc. 1994; 92: 477-588
- Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review.Clin Endocrinol. 2020; 93: 363-374
- Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy.Front Endocrinol. 2020; 11: 615993
- Psychosocial morbidity of Graves' orbitopathy.Clin Endocrinol. 2005; 63: 395-402
- Assessing quality of life in Australian patients with Graves' ophthalmopathy.Br J Ophthalmol. 2004; 88: 75-78
- Death by Suicide in Graves' Disease and Graves' Orbitopathy: A Nationwide Danish Register Study.Thyroid. 2017; 27: 1475-1480
- Management of exophthalmos and related ocular changes in Graves' disease.Metabolism. 1957; 6: 36-48
- Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center.J Clin Endocrinol Metab. 2013; 98: 1443-1449
- Graves' ophthalmopathy.N Engl J Med. 2010; 362: 726-738
- Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.J Ophthalmol. 2015; 2015: 249125
- The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism.Eur Thyroid J. 2015; 4: 149-163
- Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.Clin Endocrinol. 1997; 47: 9-14
- Modification of the classification of the eye changes of Graves' disease.Am J Ophthalmol. 1977; 83: 725-727
- VISA classification for Graves orbitopathy.Ophthal Plast Reconstr Surg. 2006; 22: 319-324
- Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.Eur J Endocrinol. 2008; 158: 273-285
- The treatment of Graves' ophthalmopathy in an incidence cohort.Am J Ophthalmol. 1996; 121: 200-206
- The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.Eur J Endocrinol. 2021; 185: G43-G67
- Selenium and the course of mild Graves' orbitopathy.N Engl J Med. 2011; 364: 1920-1931
- Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology.Ophthalmology. 2008; 115: 398-409
- Orbital radiotherapy for adult thyroid eye disease.Cochrane Database Syst Rev. 2012; 7: CD007114
- Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.Am J Ophthalmol. 2014; 157: 1299-1305
- Treatment of acute Graves orbitopathy.Ophthalmology. 1991; 98: 1443-1448
- Orbital irradiation for Graves' ophthalmopathy: Is it safe? A long-term follow-up study.Ophthalmology. 2004; 111: 1557-1562
- Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.J Clin Endocrinol Metab. 2011; 96: 320-332
- Corticosteroids for Graves' ophthalmopathy: systematic review and meta-analysis.Biomed Res Int. 2018; 2018: 4845894
- Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study.Eur J Endocrinol. 2008; 158: 229-237
- Randomized controlled trial of rituximab in patients with Graves' orbitopathy.J Clin Endocrinol Metab. 2015; 100: 432-441
- Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial.Am J Ophthalmol. 2018; 195: 181-190
- How predictable is exophthalmos reduction in Graves' orbitopathy? A review of the literature.Br J Ophthalmol. 2011; 95: 1625-1630
- Orbital decompression for thyroid eye disease: methods, outcomes, and complications.Eye. 2018; 32: 626-636
- Primary-gaze diplopia in patients with thyroid-related orbitopathy undergoing deep lateral orbital decompression with intraconal fat debulking: A retrospective analysis of treatment outcome.Thyroid. 2004; 14: 379-383
- Long-term surgical outcomes for vertical deviations in thyroid eye disease.Strabismus. 2017; 25: 67-72
- Teprotumumab for thyroid-associated ophthalmopathy.N Engl J Med. 2017; 376: 1748-1761
- Teprotumumab for the treatment of active thyroid eye disease.N Engl J Med. 2020; 382: 341-352
- The pathophysiology of thyroid eye disease.J Neuroophthalmol. 2014; 34: 177-185
- Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.Br J Ophthalmol. 2016; 100: 142-150
- Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy.J Clin Endocrinol Metab. 1998; 83: 998-1002
- Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.Best Pract Res Clin Endocrinol Metab. 2012; 26: 291-302
- Lessons learned from targeting IGF-I receptor in thyroid-associated ophthalmopathy.Cells. 2021; 10: 383
- Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease.J Immunol. 2008; 181: 4397-4405
- TSH/IGF-1 Receptor Cross Talk in Graves' ophthalmopathy pathogenesis.J Clin Endocrinol Metab. 2016; 101: 2340-2347
- TSH/IGF1 receptor crosstalk: mechanism and clinical implications.Pharmacol Ther. 2020; 209: 107502
- Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.Eye. 2021; 35: 2607-2612
- Selenium and thyroid disease: from pathophysiology to treatment.Int J Endocrinol. 2017; 2017: 1297658
- Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto's thyroiditis: a prospective randomized-controlled trial.Clin Transl Sci. 2021; 14: 1390-1402
- Vitamin D and selenium in a thyroid eye disease population in Texas.Neuroophthalmology. 2019; 43: 291-294
- Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.Clin Endocrinol. 2008; 69: 943-950
- Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections.Graefes Arch Clin Exp Ophthalmol. 2013; 251: 261-270
- Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.Thyroid. 2014; 24: 897-905
- Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.J Clin Endocrinol Metab. 2001; 86: 3562-3567
- Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.J Clin Endocrinol Metab. 2005; 90: 5234-5240
- Management of Graves’ ophthalmopathy: reality and perspectives.Endocr Rev. 2000; 21: 168-199
- Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.J Endocrinol Invest. 2015; 38: 661-668
- Treating severe Graves' ophthalmopathy.Baillieres Clin Endocrinol Metab. 1997; 11: 521-536
- Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy.Thyroid. 2004; 14: 403-406
- Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.J Clin Endocrinol Metab. 2012; 97: 4454-4463
- Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study.Lancet. 2000; 355: 1505-1509
- Role of orbital radiotherapy in the treatment of Graves' ophthalmopathy.Exp Clin Endocrinol. 1991; 97: 332-337
- Is concomitant treatment with steroids and radiotherapy more favorable than sequential treatment in moderate-to-severe graves orbitopathy?.Radiol Med. 2021; 126: 334-342
- Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.Am J Ophthalmol. 2003; 135: 285-290
- A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy.Ophthalmology. 2001; 108: 1523-1534
- Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy.Am J Ophthalmol Case Rep. 2017; 7: 146-148
- Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery.Ophthalmic Plast Reconstr Surg. 2019; 35: e64-e66
- Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study.J Clin Endocrinol Metab. 2015; 100: 422-431
- Randomized controlled trial of rituximab in patients with Graves’ orbitopathy.J Clin Endocrinol Metab. 2015; 100: 432-441
- Efficacy profile and safety of very low-dose rituximab in patients with Graves' orbitopathy.Thyroid. 2021; 31: 821-828
- Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.Ophthalmic Plast Reconstr Surg. 2014; 30: 415-419
- Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy.Orbit. 2005; 24: 117-119
- Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies.Ophthalmology. 2021; 128: 1627-1651
- Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.Clin Pharmacokinet. 2021; 60: 1029-1040
- Teprotumumab for thyroid-associated ophthalmopathy. Supplementary Material: Protocol.N Engl J Med. 2017; 376: 1748-1761
- New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy.Ophthalmic Plast Reconstr Surg. 2021; 37: e160-e164
- A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.Am J Ophthalmol Case Rep. 2021; 22: 101069
- Teprotumumab and hearing loss: case series and proposal for audiologic monitoring.Ophthalmic Plast Reconstr Surg. 2021; 38: 73-78
- Hearing Loss and Teprotumumab.J Endocr Soc. 2021; 5: A839
- Audiology findings in patients with teprotumumab associated otologic symptoms.Am J Ophthalmol Case Rep. 2021; 24: 101202
- Teprotumumab and hearing loss: hear the warnings.Orbit. 2021; 40: 355-356
- The role of insulin-like growth factor 1 in the progression of age-related hearing loss.Front Aging Neurosci. 2017; 9: 411
- Hyperglycemia associated with targeted oncologic treatment: mechanisms and management.Oncologist. 2016; 21: 1326-1336
- Teprotumumab and hyperglycemia guidelines to monitor for hyperglycemia in teprotumumab.Ophthalmic Plast Reconstr Surg. 2021; 37: 393
- Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.BMJ Case Rep. 2021; 14: e242153
- Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X Study.Ophthalmology. 2021; S0161-6420: 00818-826
- Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.Eye. 2019; 33: 183-190
- Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.Br J Ophthalmol. 2020; 106: 165-171
- Echographic assessment of extraocular muscle response to teprotumumab.Ophthalmic Plast Reconstr Surg. 2021;
- Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.Lancet Diabetes Endocrinol. 2021; 9: 360-3724
- Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab.Eur J Ophthalmol. 2021; (120672121991042)
- Teprotumumab for dysthyroid optic neuropathy: early response to therapy.Ophthalmic Plast Reconstr Surg. 2021; 37: S157-S160
- Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study.Am J Ophthalmol Case Rep. 2021; 23: 101111
- Teprotumumab for optic neuropathy in thyroid eye disease.JAMA Ophthalmol. 2021; 139: 244-247
- Visual recovery of dysthyroid optic neuropathy with teprotumumab.J Neuroophthalmol. 2021;
- Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: a report of two cases.Am J Ophthalmol Case Rep. 2021; 22: 101075
- Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population.Ophthalmic Plast Reconstr Surg. 2021; 37: 583-591
- Early experience with teprotumumab for chronic thyroid eye disease.Am J Ophthalmol Case Rep. 2020; 19: 100744
- Teprotumumab for chronic thyroid eye disease.Orbit. 2021; : 1-8
- Teprotumumab for the treatment of chronic thyroid eye disease.Eye (Lond). 2021;
- The role of teprotumumab in chronic, clinically active thyroid eye disease.Eye (Lond). 2021;
- Public health relevance of Graves' orbitopathy.J Clin Endocrinol Metab. 2013; 98: 145-152
Singh G, Sehgal M, Mithal A, et al. Thyroid eye disease in the United States: data from emergency department visits and hospitalizations. Presented at: 2021 AACE Virtual Annual Meeting, May 26–29, 2021.
- Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.Eur Thyroid J. 2020; 9: 59-65
- A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves' orbitopathy.Thyroid. 2019; 29: 111-123
Article info
Publication history
Published online: June 27, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
